再鼎医药 2026年季度报告

(Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANACT OF 1934 For the quarterly period ended March31, 2026 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANACT OF 1934 ZAI LAB LIMITED(Exact Name of Registrant as Specified in its Charter)____________________ 201203 +86 216163 2588+1 857 706 2604(Registrant’s Telephone Number, Including Area Code)____________________ Securities registered pursuant to Section 12(b) of the Act: *Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. Theordinary shares are not registered or listed for trading in the United States but are listed for trading on The Stock Exchange of HongKong Limited. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of April30, 2026, 1,123,548,580 ordinary shares of the registrant, par value $0.000006 per share, were outstanding, of which340,336,080 ordinary shares were held in the form of American Depositary Shares. Zai Lab LimitedQuarterly Report on Form 10-QFor the First Quarter of 2026 PagePART I.FINANCIAL INFORMATION1Item 1.Financial Statements (Unaudited)2Condensed Consolidated Balance Sheets as of March 31, 2026and December 31, 20252Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 20253Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2026and 20254Condensed Consolidated Statements of Shareholders’ Equity for the Three Months Ended March 31, 2026and 20255Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 20256Notes to the Unaudited Condensed Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations17Item 3.Quantitative and Qualitative Disclosures about Market Risk26Item 4.Controls and Procedures28PART II.OTHER INFORMATION29Item 1.Legal Proceedings29Item 1A.Risk Factors29Item 2.Unregistered Sales of Equity Securities and Use of Proceeds29Item 3.Defaults upon Senior Securities29Item 4.Mine Safety Disclosures29Item 5.Other Information29Item 6.Exhibits30Signatures31 SPECIAL NOTES REGARDING THE COMPANY Forward-Looking Statements This report contains certain forward-looking statements, including statements relating to our strategy and plans; potential of andexpectations for our business, commercial products, and pipeline programs; the market for our commercial and pipeline products; capitalallocation and investment strategy; clinical development programs and related clinical trials; clinical trial data, data readouts, andpresentations; risks and uncertainties associated with drug development and commercialization; regulatory discussions, submissions, filings,and approvals and the timing thereof; the potential benefits, safety, and efficacy of our products and product candidates and those of ourcollaboration partners; the anticipated benefits and potential of investments, collaborations, and business development activities; ourprofitability and timeline to profitability; and our future financial and operating results. All statements, other than statements of historicalfact, included in this report are forward-looking statements, and can be identified by words such as “aim,” “anticipate,” “believe,”“contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “predict,”“project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or similar expressions. Such statements constituteforward-looking stateme